Krämer H J, Schmidt R, Günther A, Becker G, Suzuki Y, Seeger W
Department of Internal Medicine, Justus-Liebig-University, Giessen, Germany.
Am J Respir Crit Care Med. 1995 Nov;152(5 Pt 1):1540-4. doi: 10.1164/ajrccm.152.5.7582290.
Surfactant protein B (SP-B) is one of the essential constituents of the alveolar surfactant system, presenting mainly in the form of SP-B dimer. The measurement of this molecule in biologic samples has been hampered by its extreme hydrophobicity and intimate association with surfactant lipids. We developed a solid-phase, adsorption-based enzyme-linked immunosorbent assay (ELISA) technique for the quantification of SP-B in aqueous solutions. The ELISA employs the hydrophobicity of SP-B for direct binding of this compound to polystyrol immunosorbent plates. Samples are mixed with propanol (1:1 vol/vol) to achieve a homogeneous dispersion of their lipophilic constituents prior to adsorption to the wells. After fluid removal by evaporation, trifluoroethanol is added to optimize SP-B-polystyrol binding, and is then removed, again by evaporation. Subsequent washing procedures (diisopropyl-ether/butanol; Tween 20 in phosphate buffered saline [PBS]) selectively remove phospholipids. Solid phase-bound SP-B is detected by a monoclonal mouse antibody against porcine SP-B, cross-reacting with the apoprotein of human origin. For amplification, a biotinylated anti-mouse antibody and the avidin/biotin-peroxidase technique are used. Steep calibration curves with an excellent reproducibility are obtained for SP-B dimer (range: 0.3125 to 40 ng/well), either introduced directly into the immunosorbent-plate wells or previously admixed with synthetic phospholipid mixtures. SP-B monomer is detected with approximately 10% efficiency as compared with the dimer (wt/wt). Cross-reactivities with human SP-A and SP-C or albumin are negligible. Experiments with spiking of human bronchoalveolar lavage fluid (BAL) samples with different quantities of SP-B dimer revealed virtually complete apoprotein recovery.(ABSTRACT TRUNCATED AT 250 WORDS)
表面活性蛋白B(SP - B)是肺泡表面活性物质系统的重要组成部分之一,主要以SP - B二聚体的形式存在。由于其极强的疏水性以及与表面活性脂质的紧密结合,生物样品中该分子的测量受到了阻碍。我们开发了一种基于吸附的固相酶联免疫吸附测定(ELISA)技术,用于定量水溶液中的SP - B。该ELISA利用SP - B的疏水性使其直接结合到聚苯乙烯免疫吸附板上。在吸附到孔之前,样品与丙醇(1:1体积/体积)混合,以实现其亲脂成分的均匀分散。通过蒸发去除液体后,加入三氟乙醇以优化SP - B与聚苯乙烯的结合,然后再次通过蒸发去除。随后的洗涤程序(异丙醚/丁醇;磷酸盐缓冲盐水[PBS]中的吐温20)选择性地去除磷脂。通过针对猪SP - B的单克隆小鼠抗体检测固相结合的SP - B,该抗体与人源载脂蛋白发生交叉反应。为了进行放大,使用生物素化的抗小鼠抗体和抗生物素蛋白/生物素 - 过氧化物酶技术。对于直接引入免疫吸附板孔中或先前与合成磷脂混合物混合的SP - B二聚体(范围:0.3125至40 ng/孔),可获得具有出色重现性的陡峭校准曲线。与二聚体(重量/重量)相比,检测到的SP - B单体效率约为10%。与人SP - A、SP - C或白蛋白的交叉反应可忽略不计。用不同量的SP - B二聚体加标人支气管肺泡灌洗(BAL)样品的实验显示,载脂蛋白几乎完全回收。(摘要截断于250字)